Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 7450459, 8 pages
https://doi.org/10.1155/2017/7450459
Research Article

Pretreatment Serum Cystatin C Levels Predict Renal Function, but Not Tumor Characteristics, in Patients with Prostate Neoplasia

Department of Urology, Qilu Hospital of Shandong University, Jinan 250012, China

Correspondence should be addressed to Dawei Li; moc.nuyila@dmiewadil

Received 18 December 2016; Revised 10 March 2017; Accepted 20 June 2017; Published 24 July 2017

Academic Editor: Fabio Grizzi

Copyright © 2017 Feilong Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, and J. Lortet-Tieulent, “Global cancer statistics, 2012,” CA: A Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87–108, 2015. View at Publisher · View at Google Scholar
  2. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2012,” CA: A Cancer Journal for Clinicians, vol. 62, no. 1, pp. 10–29, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. W. Chen, R. Zheng, P. D. Baade et al., “Cancer statistics in China, 2015,” CA: Cancer Journal for Clinicians, vol. 66, no. 2, pp. 115–132, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. E. A. Butler and F. V. Flynn, “The occurrence of post-gamma protein in urine: a new protein abnormality,” Journal of Clinical Pathology, vol. 14, no. 2, pp. 172–178, 1961. View at Publisher · View at Google Scholar
  5. C. F. Macpherson and J. B. Cosgrove, “Immunochemical evidence for a gamma globulin peculiar to cerebrospinal fluid,” Canadian journal of biochemistry and physiology, vol. 39, pp. 1567–1574, 1961. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Abrahamson, I. Olafsson, A. Palsdottir et al., “Structure and expression of the human cystatin C gene,” Biochemical Journal, vol. 268, no. 2, pp. 287–294, 1990. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Abrahamson, A. Grubb, I. Olafsson, and Å. Lundwall, “Molecular cloning and sequence analysis of cDNA coding for the precursor of the human cysteine proteinase inhibitor cystatin C,” FEBS Letters, vol. 216, no. 2, pp. 229–233, 1987. View at Publisher · View at Google Scholar · View at Scopus
  8. M. A. Ferguson and S. S. Waikar, “Established and emerging markers of kidney function,” Clinical Chemistry, vol. 58, no. 4, pp. 680–689, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Mori, C. Tanikawa, Y. Funauchi, P. H. Y. Lo, Y. Nakamura, and K. Matsuda, “Cystatin C as a p53-inducible apoptotic mediator that regulates cathepsin L activity,” Cancer Science, vol. 107, no. 3, pp. 298–306, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Jiborn, M. Abrahamson, H. Wallin et al., “Cystatin C is highly expressed in the human male reproductive system,” Journal of Andrology, vol. 25, no. 4, pp. 564–572, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Janowski, M. Kozak, E. Jankowska et al., “Human cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping,” Nature Structural Biology, vol. 8, no. 4, pp. 316–320, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Lertnawapan, A. Bian, Y. H. Rho et al., “Cystatin C is associated with inflammation but not atherosclerosis in systemic lupus erythematosus,” Lupus, vol. 21, no. 3, pp. 279–287, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. Y.-T. Lee, S.-C. Chen, L.-Y. Shyu et al., “Significant elevation of plasma cathepsin B and cystatin C in patients with community-acquired pneumonia,” Clinica Chimica Acta, vol. 413, no. 5-6, pp. 630–635, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Dreilich, G. Wagenius, S. Bergström et al., “The role of cystatin C and the angiogenic cytokines VEGF and bFGF in patients with esophageal carcinoma,” Medical Oncology, vol. 22, no. 1, pp. 29–38, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. F. M. Tumminello, G. Badalamenti, L. Incorvaia, F. Fulfaro, C. D'Amico, and G. Leto, “Serum interleukin-6 in patients with metastatic bone disease: Correlation with cystatin C,” Medical Oncology, vol. 26, no. 1, pp. 10–15, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Ohara, K. Miyazaki, K. Kurishima et al., “Serum levels of cystatin C in elderly lung cancer patients,” Oncology Letters, vol. 3, no. 2, pp. 303–306, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Nishikawa, Y. Ozaki, T. Nakanishi et al., “The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer,” Gynecologic Oncology, vol. 92, no. 3, pp. 881–886, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Jacobsson, H. Lignelid, and U. S. R. Bergerheim, “Transthyretin and cystatin C are catabolized in proximal tubular epithelial cells and the proteins are not useful as markers for renal cell carcinomas,” Histopathology, vol. 26, no. 6, pp. 559–564, 1995. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Wegiel, T. Jiborn, M. Abrahamson et al., “Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways,” PLoS ONE, vol. 4, no. 11, Article ID e7953, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Jiborn, M. Abrahamson, V. Gadaleanu, Å. Lundwall, and A. Bjartell, “Aberrant expression of cystatin C in prostate cancer is associated with neuroendocrine differentiation,” BJU International, vol. 98, no. 1, pp. 189–196, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. F. M. Tumminello, C. Flandina, M. Crescimanno, and G. Leto, “Circulating cathepsin K and cystatin C in patients with cancer related bone disease: Clinical and therapeutic implications,” Biomedicine and Pharmacotherapy, vol. 62, no. 2, pp. 130–135, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Strojan, B. Svetic, L. Šmid, and J. Kos, “Serum cystatin C in patients with head and neck carcinoma,” Clinica Chimica Acta, vol. 344, no. 1-2, pp. 155–161, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. E. A. Gashenko, V. A. Lebedeva, I. V. Brak, E. A. Tsykalenko, G. V. Vinokurova, and T. A. Korolenko, “Evaluation of serum procathepsin B, cystatin B and cystatin C as possible biomarkers of ovarian cancer,” International Journal of Circumpolar Health, vol. 72, no. 1, Article ID 21215, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Kyhse-Andersen, C. Schmidt, G. Nordin et al., “Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate,” Clinical Chemistry, vol. 40, no. 10, pp. 1921–1926, 1994. View at Google Scholar · View at Scopus
  25. C. W. Tsai, M. E. Grams, L. A. Inker, J. Coresh, and E. Selvin, “Cystatin C- and creatinine-based estimated glomerular filtration rate, vascular disease, and mortality in persons with diabetes in the U.S.,” Diabetes Care, vol. 37, no. 4, pp. 1002–1008, 2014. View at Publisher · View at Google Scholar
  26. A. Vega, S. García De Vinuesa, M. Goicoechea et al., “Evaluation of methods based on creatinine and cystatin C to estimate glomerular filtration rate in chronic kidney disease,” International Urology and Nephrology, vol. 46, no. 6, pp. 1161–1167, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Salek, P. Vesely, and J. Bernatek, “Estimated glomerular filtration rate in oncology patients before cisplatin chemotherapy,” Klinicka Onkologie, vol. 28, no. 4, pp. 273–277, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Zhang, X. Cao, G. Cai et al., “Clinical evaluation of serum cystatin C and creatinine in patients with chronic kidney disease: A meta-analysis,” Journal of International Medical Research, vol. 41, no. 4, pp. 944–955, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. X. Li, H. Zhu, P. Li et al., “Serum cystatin C concentration as an independent marker for hypertensive left ventricular hypertrophy,” Journal of Geriatric Cardiology, vol. 10, no. 3, pp. 286–290, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Cimerman, P. M. Brguljan, M. Krašovec, S. Šuškovič, and J. Kos, “Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients,” Clinica Chimica Acta, vol. 300, no. 1-2, pp. 83–95, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Helmersson-Karlqvist, M. Flodin, L.-O. Hansson, and A. Larsson, “The age related association is more pronounced for cystatin C estimated GFR than for creatinine estimated GFR in primary care patients,” Clinical Biochemistry, vol. 46, no. 16-17, pp. 1761–1763, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. L. D. Colantonio, R. M. Tanner, D. G. Warnock et al., “The role of cystatin-C in the confirmation of reduced glomerular filtration rate among the oldest old,” Archives of Medical Science, vol. 1, pp. 55–67, 2016. View at Publisher · View at Google Scholar
  33. K. Hoang, J. C. Tan, G. Derby et al., “Determinants of glomerular hypofiltration in aging humans,” Kidney International, vol. 64, no. 4, pp. 1417–1424, 2003. View at Publisher · View at Google Scholar · View at Scopus